Recruiting
Phase 4
RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
About this study
This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.
- Condition
- Melanoma Advanced
- Tested
- tunlametinib
- Sponsor
- Fudan University
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 8
- Minimum age: 18 years
- Study condition: Melanoma Advanced
- Aged ≥18 years (inclusive), male or female;
- Patients with histologically or cytologically confirmed locally advanced or metastatic melanoma;
- Prior genetic testing results showing positive NRAS mutation;
- Patients who have failed prior anti-PD-1/PD-L1 therapy;
- Able to take oral medications;
- Voluntarily participate and sign the informed consent form, expected to have good compliance, and able to cooperate with the study according to the protocol requirements.
Exclusion 4
- Currently participating in other clinical trials of drugs;
- Patients who are pregnant or breastfeeding;
- Other conditions deemed unsuitable for targeted therapy after multidisciplinary discussion;
- Other conditions considered inappropriate for inclusion by the investigator, such as familial or social factors that may affect the safety of the subject or the collection of data.
Where
1 site, 1 recruiting
Fudan University Shanghai Cancer Center
Shanghai, China
Contact
-
Yu Wang
86-021-64175590 neck130@sina.com
Potential match only. Final eligibility is determined by the study team.